High-dose chemotherapy for high-risk primary breast cancer: An on-site review of the Bezwoda study

Lancet

Volumn 355, Issue 9208, 2000, Pages 999-1003

  Weiss, Raymond B ^a   Rifkin, Robert M ^b   Stewart, F Marc ^c   Theriault, Richard L ^e   Williams, Lori A ^b   Herman, Allen A ^d   Beveridge, Roy A ^b  

^a Rockville   (United States)

^b Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d SEFAKO MAKGATHO HEALTH SCIENCES UNIVERSITY   (South Africa)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; ETOPOSIDE; MITOXANTRONE;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FORGERY; HIGH RISK PATIENT; HUMAN; INFORMED CONSENT; MALPRACTICE; METHODOLOGY; PRIORITY JOURNAL; PROFESSIONAL STANDARD; STEM CELL;

EID: 0034681727     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)90024-2     Document Type: Article

References (17)

1. Weiss R.B. The randomized trials of dose-intensive therapy for breast cancer: what do they mean for patient care and where do we go from here? Oncologist. 4:1999;450-458.
2. Peters W.P., Shpall E.J., Jones R.B.et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol. 6:1988;1368-1376.
3. Gianni A.M., Siena S., Bregni M.et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes. five-year results J Clin Oncol. 15:1997;2312-2321.
4. Peters W.P., Ross M., Vredenburgh J.J.et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 11:1993;1132-1143.
5. Antman K.H., Rowlings P.A., Vaughan W.P.et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol. 15:1997;1870-1879.
6. Bezwoda W.R., Seymour L., Dansey R. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer. a randomized trial J Clin Oncol. 13:1995;2483-2489.
7. Bezwoda W.R. Primary and high dose chemotherapy for metastatic breast cancer: update and analysis of prognostic factors. Proc ASCO. 17:1998;115. (abstr 445).
8. Bezwoda W.R. Randomised, controlled trial of high dose chemotherapy (HD-CNVp) versus standard dose (CAF) chemotherapy for high risk, surgically treated, primary breast cancer. Proc ASCO. 18:1999;2. (abstr 4).
9. Bezwoda W.R. Randomised controlled trial of high dose chemotherapy (HD-CNVp) versus standard dose (CAF) chemotherapy for high risk, surgically treated, primary breast cancer. Eur J Cancer. 35:1999;230. (abstr 902) (Suppl 4).
10. Stadtmauer E.A., O'Neill A., Goldstein L.J.et al. Phase III randomized trial of high-dose chemotherapy and stem cell support shows no difference in overall survival or severe toxicity compared with maintenance chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy: the "Philadelphia" Intergroup Study (PBT-1). Proc ASCO. 18:1999;1a. (abstr 1).
11. Peters W.P., Rosner G., Vredenburgh J.et al. A prospective, randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proc ASCO. 18:1999;1. (abstr 2).
12. Rodenhuis S., Richel D.J., van der Wall E.et al. Randomized trial of high-dose chemotherapy and haematopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet. 352:1998;515-521.
13. Hortobagyi G.N., Buzdar A.U., Theriault R.L.et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst. 92:2000;225-233.
14. Weiss R.B., Vogelzang N.J., Peterson B.A.et al. A successful system for scientific data audits: a report from the Cancer and Leukemia Group B. JAMA. 270:1993;459-464.
15. South African investigator Bezwoda admits falsifying data in high-dose chemo study. Cancer Lett. 26:2000;1-4.
16. Nylenna M., Andersen D., Dahlquist G., Sarvas M., Aakvaag A. Handling of scientific dishonesty in the Nordic countries. National Committees on Scientific Dishonesty in the Nordic countries Lancet. 354:1999;50-61.
17. Weiss R.B. Systems of protocol review, quality assurance, and data audit. Cancer Chemother Pharmacol. 42:1998;88-92. (Suppl).